Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients

Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients

Purpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Patients and...

Full description

Bibliographic Details
Main Authors:	Alaa Mohamed Maria, Mohamed El-Shebiney, Ayman Mohamed El-Saka, Yomna Zamzam
Format:	Article
Language:	English
Published:	SpringerOpen 2018-06-01
Series:	Journal of the Egyptian National Cancer Institute
Online Access:	http://www.sciencedirect.com/science/article/pii/S1110036218300268

Similar Items

Evaluating the expression of HMGCR in HER2 negative and HER2 positive breast cancer
by: Drahman, Rosmaizan
Published: (2022)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
by: Laura Pizzuti, et al.
Published: (2021-07-01)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
by: Maria Vittoria Dieci, et al.
Published: (2019-11-01)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
by: Alexis LeVee, et al.
Published: (2023-05-01)

Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
by: Guo-dong Cao, et al.
Published: (2017-12-01)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer.
by: Pinhel, I, et al.
Published: (2012)

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
by: Caroline Rönnlund, et al.
Published: (2024-02-01)

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer
by: Shohei Shikata, et al.
Published: (2023-11-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

The prognostic value and immune microenvironment association of AR in HER2+ nonmetastatic breast cancer
by: Danyang Zhou, et al.
Published: (2023-04-01)

Prognostic value and relapse pattern of HER2‐low in hormone receptor‐positive breast cancer
by: Tong Wei, et al.
Published: (2024-03-01)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
by: Bin Shao, et al.
Published: (2022-08-01)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
by: Yoshiya Horimoto, et al.
Published: (2022-03-01)

A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer
by: Sung-Bae Kim, et al.
Published: (2015-01-01)

Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation
by: Sahar Mansour, et al.
Published: (2023-07-01)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
by: Atif Ali Hashmi, et al.
Published: (2018-08-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
by: Joohyun Hong, et al.
Published: (2022-06-01)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
by: Advani P, et al.
Published: (2015-09-01)

Immunotherapy for HER-2 positive breast cancer
by: Tingting Yang, et al.
Published: (2023-03-01)

PTPN9 IS A NEGATIVE REGULATOR OF HER3 PHOSPHORYLATION AND A PROGNOSTIC BIOMARKER IN HER2 POSITIVE BREAST CANCER
by: Gijsen, M, et al.
Published: (2012)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
by: Atul Batra, et al.
Published: (2021-02-01)

Prognostic Role of Androgen Receptor Expression in HER2+ Breast Carcinoma Subtypes
by: Sandra Orrù, et al.
Published: (2022-01-01)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021-04-01)

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
by: Fara Brasó-Maristany, et al.
Published: (2020-01-01)

Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
by: Yi Ding, et al.
Published: (2018-10-01)

HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments
by: Ismail Essadi, et al.
Published: (2023-03-01)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
by: A. Viansone, et al.
Published: (2022-10-01)

The role of HER4 in relation to trastuzumab resistance and prognosis in HER2 positive breast cancer
by: Mohd Nafi, SN
Published: (2014)

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
by: Emma Zattarin, et al.
Published: (2023-04-01)

Immunological Landscape of HER-2 Positive Breast Cancer
by: Santiago Moragon, et al.
Published: (2022-06-01)

Immunotherapies against HER2-Positive Breast Cancer
by: Santiago Duro-Sánchez, et al.
Published: (2023-02-01)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021-09-01)

Interlaboratory concordance in HER-2 positive breast cancer
by: Nives Jonjić, et al.
Published: (2015-01-01)

Treatment of HER2 positive breast cancer patients
by: Erika Matos
Published: (2012-03-01)

Neoadjuvant therapy for HER2-positive breast cancer
by: Nikolina Dukić, et al.
Published: (2019-06-01)

Key Genes and Prognostic Analysis in HER2+ Breast Cancer
by: Yujie Weng MS, et al.
Published: (2021-01-01)

Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer
by: Adam L. Maddox, et al.
Published: (2022-06-01)